Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Bruno Vergès, Jonathan Hassid, Alexia Rouland, Benjamin Bouillet, Isabelle Simoneau, Jean‐Michel Petit, Laurence Duvillard
Topics & Concepts
LiraglutidePCSK9Type 2 diabetesMedicineInternal medicineDiabetes mellitusLdl cholesterolEndocrinologyCholesterolLDL receptorLipoproteinLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management